Trade Names
Precose (US), Glucobay, Gluconase, Glumida, Precose, Prandase.
Class and Category
Alpha glucosidase inhibitor, anti-hyperglycemic agent.
Indications
The primary use of acarbose is the management of hyperglycemia in patients with type II diabetes mellitus. A study of 1429 subjects with impaired glucose tolerance randomized to either acarbose or placebo found that acarbose significantly decreased the risk of progression to diabetes and reversed glucose intolerance more frequently than placebo. Acarbose may have a role in the prevention of diabetes in some at-risk patients.
Dosage
Ranges from 50mg to 100mg taken three times daily, taken with the start of each meal.
Contraindications
Acarbose may cause gastrointestinal distress including flatulence, cramping and diarrhea due to the presence of undigested carbohydrates in the bowel. Therefore, patients with colonic obstruction or inflammatory bowel disease, or patients prone to developing intestinal obstructions, should not take...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
(2002) Acarbose. In: Nissen D (ed) Mosby's Drug Consult 13th ed. Mosby, St. Louis
Chiasson JL, Josse RG, Gomis R, et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–7
Mertes G (2001) Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 52:193–204
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag
About this entry
Cite this entry
(2004). Acarbose. In: Moreland, L.W. (eds) Rheumatology and Immunology Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29662-X_10
Download citation
DOI: https://doi.org/10.1007/3-540-29662-X_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20625-5
Online ISBN: 978-3-540-29662-1
eBook Packages: Springer Book Archive